These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34046955)

  • 1. Salvage of refractory post-transfusion hyperhaemolysis by targeting hyperinflammation and macrophage activation with tocilizumab.
    Chen F; Booth C; Barroso F; Bennett S; Kaya B; Win N; Telfer P
    Transfus Med; 2022 Oct; 32(5):437-440. PubMed ID: 34046955
    [No Abstract]   [Full Text] [Related]  

  • 2. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
    Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
    Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
    Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
    [No Abstract]   [Full Text] [Related]  

  • 4. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
    Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
    Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
    Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
    J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.
    Dumas G; Habibi A; Onimus T; Merle JC; Razazi K; Mekontso Dessap A; Galactéros F; Michel M; Frémeaux Bacchi V; Noizat Pirenne F; Bartolucci P
    Blood; 2016 Feb; 127(8):1062-4. PubMed ID: 26758914
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
    Meenan J; Hall R; Badle S; Chatterjee B; Win N; Tsitsikas DA
    Transfusion; 2022 Mar; 62(3):546-550. PubMed ID: 35092617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
    Cullis JO; Win N; Dudley JM; Kaye T
    Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report.
    El Afifi AM; Saeed AM; Fekry GH; Mostafa MA; Elmetwally RA; Hamed IM; Hussein AN; Hasanien GM
    Transfus Med Hemother; 2023 Feb; 50(1):66-70. PubMed ID: 36818772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
    Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
    Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.
    Shimizu M; Nakagishi Y; Kasai K; Yamasaki Y; Miyoshi M; Takei S; Yachie A
    Cytokine; 2012 May; 58(2):287-94. PubMed ID: 22398373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhaemolysis syndrome in a patient with myelofibrosis.
    Treleaven JG; Win N
    Hematology; 2004 Apr; 9(2):147-9. PubMed ID: 15203871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion.
    Wu Y; Ji Y; Dai B; Guo F; Wu Y; He Z; Mo C; Wu S; Hu Y
    Transfus Med; 2021 Feb; 31(1):24-29. PubMed ID: 33331032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab inhibits hemolysis in a model of ABO-incompatible red blood cell transfusion.
    Fata CR; Gehrie EA; Young PP
    Transfusion; 2015 Jul; 55(7):1823-4. PubMed ID: 26172150
    [No Abstract]   [Full Text] [Related]  

  • 16. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
    Madu AJ; Ugwu AO; Efobi C
    Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
    Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis.
    Faguer S; Vergez F; Peres M; Ferrandiz I; Casemayou A; Belliere J; Cointault O; Lavayssiere L; Nogier MB; Prevot G; Huart A; Recher C; Rostaing L
    Hematol Oncol; 2016 Mar; 34(1):55-7. PubMed ID: 25312407
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S; Arthur CM; Zerra PE; Maier CL; Jajosky RP; Yee MEM; Miller MJ; Josephson CD; Roback JD; Fasano R; Stowell SR
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.